Non-Hodgkin Lymphoma (NHL)

FDA Approves Targeted Immunotherapy for Aggressive Forms of Follicular Lymphoma

First 2025 New Blood Cancer Drug Approval Adds Years of Life for People Living with Mantle Cell Lymphoma

New $20 Million Research Funding Program Aims to ‘Accelerate a Cure’ for Follicular Lymphoma

Breaking Data Presented at ASCO 2024 Showcase Breadth of The Leukemia & Lymphoma Society Therapy Acceleration Program Impact on Key Blood Cancer Research

Blood cancer facts and statistics

Pain in children and teens

Firefighters and blood cancer risk in young adults

Sleep disturbances in young adults

Immunotherapy for young adults

Partnerships

Subscribe to Non-Hodgkin Lymphoma (NHL)

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.